Table 1.
Patient demographics and baseline characteristics of 42 AML patients with and without TLS
| Baseline characteristics |
All (n = 42) |
Without TLS (n = 37) |
With TLS (n = 5) |
P |
|---|---|---|---|---|
| Age (years) | 0.06 | |||
| Median (range) | 65 (24–80) | 68 (24–80) | 46 (26–73) | |
| Sex n (%) | 0.36 | |||
| Female | 19 (45) | 18 (49) | 1 (20) | |
| Male | 23 (55) | 19 (51) | 4 (80) | |
| Type of AML n (%) | < 0.01 | |||
| De novo | 15 (36) | 10 (27) | 5 (100) | |
| Secondary | 26 (62) | 26 (70) | – | |
| Treatment-related | 21 | – | ||
| History of MDS | 5 | – | ||
| Biphenotypic leukemia | 1 (2) | 1 (3) | – | |
| ELN classification 2017 n (%) | 0.67 | |||
| Favorable | 4 (10) | 3 (8) | 1 (20) | |
| Intermediate | 16 (38) | 15 (40) | 1 (20) | |
| Adverse | 21 (50) | 18 (49) | 3 (60) | |
| Missing | 1 (2) | 1 (3) | – | |
| Complex karyotype n (%) | 0.2 | |||
| Yes | 13 (31) | 13 (35) | 0 | |
| No | 27 (64) | 22 (60) | 5 | |
| Missing | 2 (5) | 2 (5) | – | |
| Treatment lines before VEN | 0.84 | |||
| Median (range) | 2 (0–5) | 2 (0–5) | 2 (1–4) | |
| WBC at start of VEN (×109/L) | 0.47 | |||
| Median (range) | 2.5 (0.1–40.1) | 2 (0.1–40.1) | 4.8 (0.7–26.3) | |
| Hemoglobin at start of VEN (g/dL) | 0.98 | |||
| Median (range) | 8.8 (6.9–12.3) | 8.8 (6.9–12.3) | 8.9 (7.2–9.7) | |
| Platelet count at start of VEN (×109/L) | 0.82 | |||
| Median (range) | 33.5 (3–244) | 33 (3–244) | 65 (6–141) | |
| Blasts in BM at start of VEN (%) | 0.18 | |||
| Median (range) | 30 (5–90) | 36 (5–90) | 25.5 (25–26) | |
| Blasts in PB at start of VEN (%) | 0.57 | |||
| Median (range) | 12.4 (0–85) | 16 (0–85) | 6 (4.6–57) | |
| AlloHCT before VEN n (%) | 1.0 | |||
| Yes | 17 (40) | 15 (40) | 2 (40) | |
| No | 25 (60) | 22 (60) | 3 (60) | |
| Previous HMA treatment n (%) | 0.04 | |||
| Yes | 28 (67) | 27 (73) | 1 (20) | |
| No | 14 (33) | 10 (27) | 4 (80) | |
| Combination partner for VEN n (%) | 0.51 | |||
| Azacitidine | 27 (64) | 25 (68) | 2 (40) | |
| Decitabine | 12 (29) | 10 (27) | 2 (40) | |
| LDAC | 3 (7) | 2 (5) | 1 (20) | |
| Azole treatment n (%) | 0.07 | |||
| Posaconazole | 31 (74) | 29 (78) | 2 (40) | |
| Voriconazole | 11 (26) | 8 (22) | 3 (60) | |
| Pre-treatment calcium mmol/L | 0.88 | |||
| Median (range) | 2.15 (1.73–3.28) | 2.14 (1.73–3.28) | 2.16 (1.93–2.39) | |
| Pre-treatment potassium mmol/L | 0.2 | |||
| Median (range) | 4.1 (3.0–6.1) | 4.1 (3.0–5.9) | 4.5 (3.2–6.1) | |
| Pre-treatment phosphate mmol/L | 0.03 | |||
| Median (range) | 1.1 (0.54–2.11) | 1.08 (0.54–2.11) | 1.4 (1.01–1.85) | |
| Pre-treatment uric acid | 0.38 | |||
| Median (range) | 264 (103–444) | 285 (103–444) | 203 (157–289) | |
| Pre-treatment creatinine μmol/L | 0.01 | |||
| Median (range) | 84.5 (42–843) | 81 (42–203) | 144 (84–843) |
Dates are n (%) or median (range) unless otherwise noted. ECOG Eastern Cooperative Oncology Group, WBC white cell count, BM bone marrow, PB peripheral blood, AlloHCT allogeneic hematopoietic cell transplantation